Plecanatide is a laxative used to treat chronic idiopathic constipation and IBS with constipation. It should not be used in children less than six years of age, and should be avoided in patients six years to 18 years of age.
- Mechanism
- Curator reviewed
Guanylate cyclase C (GC-C) agonist Plecanatide and its active metabolite bind to GC-C and act locally on the luminal surface of intestinal epithelial cells; GC-C activation leads to increased cyclic guanosine monophosphate (cGMP), which, in turn, stimulates secretion of chloride and bicarbonate into the intestinal lumen, mainly by activation of the cystic fibrosis transmembrane conductance regulator (CFTR) ion channel, resulting in increased intestinal fluid and accelerated transit. In animal models, plecanatide has been shown to increase fluid secretion into the gastrointestinal (GI) tract, accelerate intestinal transit, and cause changes in stool consistency. In an animal model of visceral pain, plecanatide reduced abdominal muscle contractions, a measure of intestinal pain. The mechanism has not been studied.
- Primary indication
- Plecanatide is indicated for the treatment of chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C) in adult patients.Curator reviewed · 2 structured indications
- Formula / weight
- C65H104N18O26S4 · 1681.89 g/mol (avg)
- First approval
- Canada, 2021 · United States, 2017
- Also known as
- Guanilib
- Brand names
Resolves to
NSPHQWLKCGGCQR-DLJDZFDSSA-NSMILES[H][C@@]12CSSC[C@H](NC(=O)CNC(=O)[C@@]([H])(NC(=O)[C@]([H])(CSSC[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC2=O)C(C)C)C(C)C)[C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=OWhat you can answer from here — as of September 12, 2026
Which drugs share a target with Plecanatide, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account